Navigation Links
Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
Date:7/5/2011

AMSTERDAM, July 6, 2011 /PRNewswire/ --


 

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced the appointment of Dr. Carlos R. Camozzi as Chief Medical Officer. Dr. Camozzi brings to AMT more than 25 years of pharmaceutical industry experience, most recently within the orphan drug field. This includes overseeing product approvals at the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

"We are very fortunate to have attracted Carlos to AMT. He has joined the company at a pivotal point as we continue to pursue the approval our lead gene therapy Glybera with the EMA," stated Jörn Aldag, CEO of AMT. "His expertise in product development and related interaction with global regulatory bodies in the orphan drug field will prove invaluable, not only with Glybera, but also as we advance development of our gene therapy pipeline."

Dr. Camozzi will join AMT on July 18 from Orphan Europe, where he held the position of Medical Director for over 5 years. During his tenure, he oversaw the approval of Carbaglu, a product for hyperammonemia in NAGS deficiency and Organic Acidemias, with the EMA and FDA, EMEA marketing authorisation renewals for two products, three orphan drug designations and development of pediatric investigation plans. He was also responsible for the clinical development in the pediatric field of orphan drugs in therapeutic areas of metabolic disorders, immunology, dermatology, cardiology and CNS.

Prior to Orphan Europe, Dr. Camozzi was a strategic development manager in the Molecular Pathology department of Basel University Hospital, Basel, Switzerland. In this role, he interacted with both pharmaceutical customers and regulatory authorities. From 2001-2005, he was managing director of MCP-medeor consulting pharma, where he helped design preclinical and clinical development programs for pharmaceutical and healthcare products. Dr. Camozzi started his career in South America holding roles at Lederle/American Cyanamid and F Hoffmann La-Roche.

Dr. Camozzi earned his MD and PhD from the School of Medicine, National University of Buenos Aires (Argentina), and holds degrees in Paediatrics, Neonatology, Clinical Pharmacology and Neuropsychiatry.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy,""expects,"" plans,""anticipates,""believes, ""will,""continues," "estimates,""intends,"" projects,""goals,""targets " and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. 



'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
2. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
3. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
8. Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications
9. Biochemist and Geneticist Ronald W. Davis Receives $500,000 Gruber Genetics Prize for Pioneering Work in the Development of Biotechnologies that Have Significantly Advanced the Fields of Molecular Genetics and Genomics
10. NIH grant ratchets up ASU research in molecular motors
11. SAIC-Frederick and Biomatrica Collaborate to Improve Molecular Analysis in Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):